CN1506048A - Application of levo histidine in treating diabetes - Google Patents
Application of levo histidine in treating diabetes Download PDFInfo
- Publication number
- CN1506048A CN1506048A CNA021509352A CN02150935A CN1506048A CN 1506048 A CN1506048 A CN 1506048A CN A021509352 A CNA021509352 A CN A021509352A CN 02150935 A CN02150935 A CN 02150935A CN 1506048 A CN1506048 A CN 1506048A
- Authority
- CN
- China
- Prior art keywords
- histidine
- levo
- diabetes
- present
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention provides the application of levo histidine in treating diabetes and one kind of medicine containing levo histidine, chromium and alpha-glocosidase. Experiment shows that levo histidine can raise the activity of antioxidant enzyme in body, eliminate lipoid peroxide and raise body's ability of resisting free radical and thus has the effects of delaying senility and lowering blood sugar. Experiment also shows that the medicine composition of the present invention can lower and stabilize blood sugar level. The present invention has excellent curative effect on diabetes, especially diabetes companied with hyperlipidemia, hypercholesterolemia, hypertension, obesity and hyperinsulinemia.
Description
Technical field:
The present invention relates to the diabetes field, relate in particular to a kind of histidine, is the purposes that left-handed histidine is used for the treatment of diabetes specifically.
Background technology:
Raising along with people's living standard, the quickening of work rhythm, the change of dietary structure, diabetes are suffered from by China and hyperlipidemia person day by day increases, diabetes are human modal metabolism disorders, be divided into diabetes that rely on insulin and the diabetes that do not rely on insulin, these amphitypy diabetes all can injure health and utilize the ability of glucose as the energy, and chronic hyperglycemia can injure a lot of tissues and the organ of health at leisure.In the prior art, the common drug that is used for control of diabetes is divided into two classes: biguanides and sulfonylurea, biguanides can prevent over-drastic liver glyconeogenesis.Sulfonylurea is mainly by stimulating insulin secretion, by in some target tissue, improving insulin action and synthesizing to come blood sugar lowering by suppressing liver sugar, the mechanism of action of oral antidiabetic thing of the prior art (as sulfonylureas) mainly is based on the β cell uelralante of increase from pancreas, this mechanism may cause quickening to consume the insulin that the diabetics endogenous produces for a long time, take medicine for a long time, how can produce various side effect in various degree.
Summary of the invention:
Technical problem to be solved by this invention is: owing to the raising along with people's living standard, the quickening of work rhythm, the change of dietary structure, diabetes are suffered from by China and hyperlipidemia person day by day increases, take medicine for a long time, how can produce various side effect in various degree.The present invention is for solving the above-mentioned technical problem in the prior art, the technical scheme that is adopted provides the purposes that left-handed histidine is used for the treatment of diabetes, the present invention also provides a kind of medicine that contains l-histidine, described medicine comprises chromium, Alpha-glucosidase inhibitor and l-histidine, described chromium, the weight ratio of Alpha-glucosidase inhibitor and described biotin is at 5-10: 3-9: between the 2.5-2000, preferably, described chromium, the ratio of Alpha-glucosidase inhibitor and l-histidine is about 5: 8-9: between the 5-200, in a preferred embodiment of the invention, described medicine can be made tablet, aqueous or oil-based suspension, can disperse powder or granule, emulsion, hard or soft capsule, syrup.Described preparation method thing can be according to the known any method preparation in preparation Pharmaceutical composition field, and described medicine can add excipient, granulating agent, disintegrating agent and lubricant.
Experiment showed, that intravital free radical can cause the damage of beta Cell of islet, cause islet function to descend, make blood sugar increasing.Because l-histidine has improved the activity of antioxidase in the body, and lipid peroxide is had certain scavenging action again, has improved the ability of body free radical resisting, therefore have slow down aging and hypoglycemic effect.Test shows, compositions of the present invention is owing to unite use with chromium, Alpha-glucosidase inhibitor and l-histidine, significantly blood sugar lowering level and stabilised blood sugar level.
The present invention and prior art contrast, and for diabetics, particularly have hyperlipemia, cholesterol increase (hypercholesterolemia, hypertriglyceridemia), hypertension simultaneously, and patient fat and hyperinsulinemia has good effect.
The specific embodiment:
A kind of medicine that contains l-histidine of the present invention, described medicine comprises chromium, Alpha-glucosidase inhibitor and l-histidine, the weight ratio of described chromium, Alpha-glucosidase inhibitor and described biotin is between 5: 3: 200, and described medicine can make tablet, aqueous or oil-based suspension, can disperse powder or granule, emulsion, hard or soft capsule, syrup.Described preparation method thing can be according to the known any method preparation in preparation Pharmaceutical composition field, and described medicine can add excipient, granulating agent, disintegrating agent and lubricant.
Experiment showed, that intravital free radical can cause the damage of beta Cell of islet, cause islet function to descend, make blood sugar increasing.Because l-histidine has improved the activity of antioxidase in the body, and lipid peroxide is had certain scavenging action again, has improved the ability of body free radical resisting, therefore have slow down aging and hypoglycemic effect.Compositions of the present invention is owing to unite use with chromium, Alpha-glucosidase inhibitor and l-histidine, significantly blood sugar lowering level and stabilised blood sugar level.
Claims (2)
1, left-handed histidine is used for the treatment of the purposes of diabetes.
2, a kind of medicine that contains l-histidine, it is characterized in that described medicine comprises chromium, Alpha-glucosidase inhibitor and l-histidine, the weight ratio of described chromium, Alpha-glucosidase inhibitor and described biotin is at 5-10: 3-9: between the 2.5-2000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021509352A CN1506048A (en) | 2002-12-05 | 2002-12-05 | Application of levo histidine in treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021509352A CN1506048A (en) | 2002-12-05 | 2002-12-05 | Application of levo histidine in treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1506048A true CN1506048A (en) | 2004-06-23 |
Family
ID=34234164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021509352A Pending CN1506048A (en) | 2002-12-05 | 2002-12-05 | Application of levo histidine in treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1506048A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106619688A (en) * | 2016-12-27 | 2017-05-10 | 郑州郑先医药科技有限公司 | Pharmaceutical composition for treating diabetes and application |
| US11896581B2 (en) | 2020-09-04 | 2024-02-13 | Société des Produits Nestlé S.A. | Compositions and methods for providing health benefits in an animal |
-
2002
- 2002-12-05 CN CNA021509352A patent/CN1506048A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106619688A (en) * | 2016-12-27 | 2017-05-10 | 郑州郑先医药科技有限公司 | Pharmaceutical composition for treating diabetes and application |
| US11896581B2 (en) | 2020-09-04 | 2024-02-13 | Société des Produits Nestlé S.A. | Compositions and methods for providing health benefits in an animal |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8697086B2 (en) | Use of Antrodia camphorata for treating diseases | |
| US5550113A (en) | Blood sugar regulating composition and methods relating thereto | |
| ES2239799T3 (en) | USE OF TETRAHIDROLIPSTATIN IN THE TREATMENT OF TYPE II DIABETES. | |
| RU2002114820A (en) | A method for treating diabetes | |
| BG64473B1 (en) | Application of sibutramine analogues for the prevention of diabetes development | |
| RU2001110097A (en) | THERAPEUTIC COMPOSITIONS (II) | |
| WO2000041504A3 (en) | Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides | |
| Sangsuwan et al. | Randomized controlled trial of Tinospora crispa for additional therapy in patients with type 2 diabetes mellitus | |
| CN109731075A (en) | Grow Chinese medicine composition, cell nutritious element and the application method of pancreas nourishing the liver control sugar therapy | |
| RU2543635C2 (en) | Method and pharmaceutical compositions for treating postprandial hyperglycemia accompanying type ii diabetes mellitus by administering through oral mucosa | |
| CN1506048A (en) | Application of levo histidine in treating diabetes | |
| CN100389774C (en) | Medicinal composition for treating diabetes and its preparation method | |
| KR20020068497A (en) | Remedies for Diabetes | |
| WO2019170153A1 (en) | GLP-1 Composition for Treating Obesity and Weight Management | |
| CN104721192A (en) | Pharmaceutical composition containing lorcaserin and medical application of pharmaceutical composition | |
| US6486127B1 (en) | Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof | |
| CN101474397A (en) | Injection for treating hyperthyroidism | |
| JPH08245403A (en) | Composition for medical treatment of insulin-resistant syndrome | |
| CN101411697A (en) | Medicinal composition for treating angiocardiopathy | |
| Tavintharan et al. | A rare cause of syncope in a patient with diabetes mellitus--a case report | |
| AU2003259006A1 (en) | Composition and method for use in intestinal cleansing procedures | |
| SU1722504A1 (en) | Method for treatment of coronary vessel aterosclerosis | |
| CN1506073A (en) | Application of zinc salt in medicine for treating diabetes | |
| JPH10167976A (en) | Immunological competence activator and regenerative activator for normalization of injured tissue | |
| SU1718948A1 (en) | Method for treating the viral hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |